Australian start-up targets diseases resulting from unhealthy lifestyles

19 February 2018

A new company has been founded in Australia with the aim of developing new therapies to target conditions relating to an unhealthy Western diet, including serious and highly prevalent diseases associated with obesity.

Cincera Therapeutics, a spin-out of the University of South Australia and SA Pathology’s Centre for Cancer Biology, and Monash University’s Institute of Pharmaceutical Sciences in Melbourne, will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis).

The company has been launched with a A$7 million ($5.5 million) venture capital commitment from Australia’s Medical Research Commercialisation Fund (MRCF).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK